cell, the expression of a foreign gene for a therapeutic protein, an antibody, or the like can be significantly enhanced.

cell, the expression of a foreign gene for a therapeutic protein, an antibody, or the like can be significantly enhanced.

Brief Description of Drawings

[Fig. 1] Fig. 1 shows a graph in which it was confirmed by the amplification of a GAPDH region that a sample subjected to ChIP-on-chip was chromatin-immunoprecipitated specifically with an anti-acetylated histone H3 antibody.

[Fig. 2] Fig. 2 is a schematic view of an SEAP expression vector into which a DNA element has been inserted.

[Fig. 3] Fig. 3 is a graph showing the expression of SEAP under the control of a CMV promoter in a stably expressing CHO cell line either without a DNA element or with DNA element A2, A7, A18, B5, or C14. The effects of DNA elements A2, A7, A18, B5, and C14 on enhancement of expression were confirmed.

[Fig. 4] Fig. 4 comprises two graphs showing the expression of SEAP under the control of either an EF-1α or an SV40 promoter in a stably expressing CHO cell line either without a DNA element or with DNA element A2 or A7. The effects of DNA elements A2 and A7 on enhancement of expression were confirmed.

[Fig. 5] Fig. 5 is a schematic view of an antibody expression (antibody gene X heavy chain and light chain co-expression) vector into which a DNA element has been inserted.

The present invention also provides any one of the embodiments disclosed below and indicated with the numbers 1 to 25.

1. A polynucleotide consisting of a polynucleotide sequence represented by SEQ ID NO: 1 in the Sequence Listing.

2. A polynucleotide consisting of a polynucleotide sequence represented by SEQ ID NO: 2 in the Sequence Listing.

3. A polynucleotide consisting of a polynucleotide sequence represented by SEQ ID NO: 3 in the Sequence Listing.

4. A polynucleotide consisting of a polynucleotide sequence represented by SEQ ID NO: 4 in the Sequence Listing.

5. A polynucleotide consisting of a polynucleotide sequence represented by SEQ ID NO: 5 in the Sequence Listing.

6. A polynucleotide comprising at least 3000 consecutive nucleotides of a polynucleotide sequence represented by any one of SEQ ID NOS: 1 to 5 in the Sequence Listing.

7. A polynucleotide comprising at least 2000 consecutive nucleotides of a polynucleotide sequence represented by any one of SEQ ID NOS: 1 to 5 in the Sequence Listing.

8. A polynucleotide comprising at least 1500 consecutive

nucleotides of a polynucleotide sequence represented by any one of SEQ ID NOS: 1 to 5 in the Sequence Listing.

9. A polynucleotide consisting of a polynucleotide sequence having a homology of 95% or more to the polynucleotide sequence of the polynucleotide according to any one of claims 1 to 8.

10. A polynucleotide consisting of a polynucleotide sequence having a homology of 99% or more to the polynucleotide sequence of the polynucleotide according to any one of claims 1 to 8.

11. A polynucleotide consisting of a polynucleotide sequence containing two or more sequences of the polynucleotide sequence of the polynucleotide according to any one of claims 1 to 10.

12. A polynucleotide consisting of two or more types of polynucleotides selected from the polynucleotides according to claims 1 to 10.

13. A foreign gene expression vector comprising the polynucleotide sequence of a polynucleotide according to any one of claims 1 to 12.

14. The foreign gene expression vector according to claim 13, wherein the protein encoded by the foreign gene is a multimeric protein.

15. The foreign gene expression vector according to claim 13, wherein the protein encoded by the foreign gene is a hetero-multimeric protein.

16. The foreign gene expression vector according to claim 15, wherein the protein encoded by the foreign gene is an antibody or a functional fragment thereof.

17. A transformed cell into which the foreign gene expression vector according to any one of claims 13 to 16 has been introduced.

18. The transformed cell according to claim 17, wherein the cell is a cultured cell derived from a mammal.

19. The transformed cell according to claim 18, wherein the cultured cell derived from a mammal is a cell selected from the group consisting of COS-1 cells, 293 cells, and CHO cells.

20. The transformed cell according to any one of claims 17

to 19, wherein the protein encoded by the foreign gene is a multimeric protein.

21. The transformed cell according to claim 20, wherein the protein encoded by the foreign gene is a hetero-multimeric protein.

22. The transformed cell according to claim 21, wherein the protein encoded by the foreign gene is an antibody or a functional fragment thereof.

23. A method for producing a protein characterized by comprising culturing the transformed cell according to any one of claims 17 to 22 and obtaining the protein encoded by the foreign gene from the resulting culture product.

24. A method for enhancing foreign gene expression in a transformed cell into which a foreign gene or a foreign gene expression vector has been introduced, characterized by using a polynucleotide according to any one of claims 1 to 12 or a foreign gene expression vector according to any one of claims 13 to 16.

25. Use of the polynucleotide according to any one of claims 1 to 12 for enhancing foreign gene expression in a transformed

cell.

Brief Description of Drawings

[Fig. 1] Fig. 1 shows a graph in which it was confirmed by the amplification of a GAPDH region that a sample subjected to ChIP-on-chip was chromatin-immunoprecipitated specifically with an anti-acetylated histone H3 antibody.

[Fig. 2] Fig. 2 is a schematic view of an SEAP expression vector into which a DNA element has been inserted.

[Fig. 3] Fig. 3 is a graph showing the expression of SEAP under the control of a CMV promoter in a stably expressing CHO cell line either without a DNA element or with DNA element A2, A7, A18, B5, or C14. The effects of DNA elements A2, A7, A18, B5, and C14 on enhancement of expression were confirmed.

[Fig. 4] Fig. 4 comprises two graphs showing the expression of SEAP under the control of either an EF-1α or an SV40 promoter in a stably expressing CHO cell line either without a DNA element or with DNA element A2 or A7. The effects of DNA elements A2 and A7 on enhancement of expression were confirmed.

[Fig. 5] Fig. 5 is a schematic view of an antibody expression (antibody gene X heavy chain and light chain co-expression) vector into which a DNA element has been inserted.